A post-marketing analysis of safety reports found that many of the strongest signals involving Qalsody (tofersen) in people with…
Articles by Andrea Lobo, PhD
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide…
Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from…
Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated…
Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC,…
PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan…
Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid…
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by…
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its…